Drug Profile
Research programme: autoimmune disorder therapeutics - Zymeworks
Latest Information Update: 28 Dec 2018
Price :
$50
*
At a glance
- Originator Zymeworks
- Class Antibodies; Proteins
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Autoimmune disorders
Most Recent Events
- 28 Dec 2018 No recent reports of development identified for research development in Autoimmune-disorders in Canada
- 01 Nov 2014 Early research in Autoimmune disorders in Canada (unspecified route)